The Cryptic Path to Your Future. Cryptic Masons Medical Research Foundation

Similar documents
Translational & Molecular Imaging Institute

Concept of Integrated Research Platforms

AMERICAN HEART ASSOCIATION RESEARCH FACTS FY

Current Market Dynamics and Future Vision of the Care Cycle

Flordeliza Villanueva and colleagues were the first to prove the principle that with the use of ultrasound heart disease could be diagnosed in a

Senior Clinical Investigator

Life Valve Project (FP7)

Extramural Research Pulmonary Arterial Hypertension. James P. Kiley, M.S., Ph.D. June 20, 2008

Advancing minimally invasive. therapeutics through novel device. development. Minima y Invasive New Technologies T H E L E O N A M. A N D H A R R Y B.

Our job today Enlist you to help us cross the Translational Divide between the lab bench and the patient s bedside Demonstrate that this will

CASE FOR SUPPORT STATEMENT

UNDERSTANDING GENETIC RESEARCH AND ALTERNATING HEMIPLEGIA OF CHILDHOOD. IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process

Progress Report. Jouko Karvinen CEO of Medical Systems

NEW MOLECULAR IMAGING LABS TO UNDERPIN SINGAPORE S BIOMEDICAL RESEARCH EFFORTS

INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR REGENERATIVE MEDICINE

Towards a P4 Healthcare System: Predictive, Preventive, Personalized & Participatory

Participating Labs/Departments: Microcirculation Laboratory, Center for Ultrasound Molecular Imaging and Therapeutics, University of Pittsburgh

Structure of IgG and IgM

AC : CARDIOVASCULAR ENGINEERING: CURRENT STATUS, FUTURE TRENDS, AND ITS EMERGENCE AS A DISCIPLINE

the clinical research institute at RAMBAM

EMA s role & responsibility for the development of modern/advanced therapies

Medical Devices for The Non-Communicable Diseases Agenda Nicole Denjoy

Vision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University

Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association

Education Critical to Stem Cell Therapy Pipeline

MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE

ATP APPLICATION (all materials due June 17, 2016)

Imaging. Steve Rusckowski CEO Philips Healthcare

ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS

The Cost-Benefit Calculus of CT Angiograms

GENOMICS: THE KEY TO TOMORROW S TREATMENTS? Jim Sullivan, PH.D. Vice President, Discovery AbbVie

Translational Research in Korea

Associate Dean for Research Florida Hospital Chair in cardiovascular Sciences

International Foundations of Medicine Basic Science Exam Blueprint

The Curative and Transformative Potential of Novel Therapies for Rare Diseases in the Age of Precision Medicine

Multidisciplinary Cardiovascular Research Centre Commercialisation

Developing Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013

ATP APPLICATION. (all materials due July 19, 2010) Name of Student: Pitt Student ID: US Citizen* YES Permanent Registered Alien** YES

Creating the future of Healthcare through meaningful innovation. Gene Saragnese, CEO Healthcare Imaging Systems

The niche/microenvironment shapes the fate of researchers and stem cells

intelligent use of health information to individualize and integrate health care Hopkins inhealth

TAXINOMISIS a multidisciplinary EU project on stratification of patients with carotid artery disease

Harvard Stem Cell Institute

Blood Pressure and Hypertension Genetics

National Health Research Institutes

Computational biomechanics of the cardiovascular system

The Ultimate Guide To STEM CELL THERAPY. for Joint Disorders

Testimony of the. Federation of American Societies for Experimental Biology. Prepared for the. House Committee on Appropriations

EXECUTIVE SUMMARY GLOBAL GENOMICS AND BIOINFORMATICS RESEARCH INSTITUTE. May 24, 2017

BIOSCIENCE IN THE 21 ST CENTURY: HIGHLIGHTS AND FUTURE PROSPECTS

Stem Cells and Regenerative Medicine

HITT 1211 Final Exam Review (Chap 1-12)

The 2012 Nobel Prize in Physiology or Medicine. John B. Gurdon and Shinya Yamanaka

The 2012 Nobel Prize in Physiology or Medicine. John B. Gurdon and Shinya Yamanaka

Precision Vascular Robotics. Corindus Vascular Robotics (CVRS) October 2018

What is biomedical science?

STEM CELLS BONE FRACTURE

China-EU Competition Week: Abbott's Acquisition of St. Jude Medical

Welcome all. Principles of Tissue Engineering AMME4971 & AMME5971. Convenor: Professor Hala Zreiqat

Medical Ethics. Ernie Graham, MD Dept Gyn-Ob Div Maternal-Fetal Medicine Johns Hopkins University School of Medicine

Knowing changes everything.

Exploring Sources of Variability Related to the Clinical Translation of Regenerative Engineering Products A Workshop

IRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014

Internationally Renowned Expert in Artificial Liver Device Development Joins HepaLife

How You Can Use Stem Cells

Production Assistance for Cellular Therapies PACT

Regenerative Medicine. Speaker Disclosures. What is regenerative medicine? 6/22/2016

Special Issue. Mesoblast Limited

The European Stroke Network

For more information about how to cite these materials visit

80 Years of Innovation

Market Analysis & Segmentation Bioshares Biotech Summit July Duncan Ross Managing Director & CEO

STUDY OF STENT DEFORMATION AND STRESS DEVELOPED AT DIFFERENT STENT DEPLOYMENT PRESSURES

Registry Assessment of Peripheral Interventional Devices (RAPID)

Trends for medical devices

The NYSCF Research Institute

Leading the world in novel adult stem cell therapies Half-Year Financial Results

Marcia L. Zucker, Ph.D. ZIVD LLC

Linking Curricular Competencies and Milestones to ACGME Reporting Milestones: Emerging New Tools

Business Update October Duncan Ross CEO Peter Manley CFO

From: Jonathan S. Lewin, M.D., F.A.C.R. Martin Donner Professor and Director Russell H. Morgan Department of Radiology and Radiological Science

The double standard in consent. Iain Chalmers Coordinator, James Lind Initiative

Overview & Introduction. BME 450: Biomedical Engineering Design I

MGI: The power of AI and genetic sequencing

microvascular high tech solutions

Lessons Learned Through Leadership

Lessons Learned Through Leadership

Up Close and Personal

Promising Future for Ex vivo Tissue Fabrication. Eiji Kobayashi, MD, PhD Department of Organ Fabrication, Keio University School of Medicine, Japan

Will Stem Cells Finally Deliver Without Controversy?

Medical Engineering (Biomedical Engineering, Clinical Engineering, Bioengineering) Medical Materials Science (Biomaterials) Dental Materials Science

BATTLING BUGS: INROADS IN INFECTIOUS DISEASES

OUR WISH LIST RESEARCH EQUIPMENT

OUR WISH LIST RESEARCH EQUIPMENT

Progress in X-Ray & MR

building better science

Bone Marrow Failure Research Program

Stem Cell Research From Bench to Bedside

Unicyte AG, regenerative medicine unit of Fresenius Medical Care, appoints world-leading experts to Scientific Advisory Board

GE s Technology and Services

Transcription:

The Cryptic Path to Your Future Cryptic Masons Medical Research Foundation

General Grand Council, Cryptic Masons, International

Your General Grand Council, Cryptic Masons, International and Cryptic Masons Medical Research Foundation is Advancing the Scope of Atherosclerosis Research with the Cryptic Masons Chair in Vascular Biology Research.

Purpose of CMMRF Research is BECAUSE Cardiovascular disease is the Number One Killer in the United States. You Know Someone Who s had a Heart Attack or Stroke. You Are Committed to Improving Medicine for Future Generations. YOU CARE.

Cryptic Masons Medical Research Foundation Since January 1, 1986 all contributions have been cumulative. Located at Indiana University, Indianapolis, Indiana. Many recognition levels for donations. Donations are tax deductible. Your Donations will live forever. They are Never spent.

Indiana Center for Vascular Biology& Medicine(ICVBM) Cryptic Masons Medical Research Center Indiana University, Indianapolis,Indiana

Our Mission Statement The Indiana Center for Vascular Biology and Medicine (ICVBM) is committed to the rapid development, testing and extension to clinical application and commercialization of new knowledge in vascular biology. The ICVBM operates with the purpose of promoting research while impacting delivery of novel and innovative medical treatment in order to achieve positive results within the health care community.

You & Your General Grand Council, Cryptic Masons, International Have Already Accomplished With the ICVBM the Following for Vascular Biology: 1. Established a Center for Vascular Research. 2. Establish Dr. March as Director of our Center. 3. Dr. March has more than 16 medical Patents 4. The Closer is being used on 500,000 patients annually. 5. Several Patents deal with the delivery of medicine to a damaged area. 6. Attracting a World Class Research Team to our Center. 7. The Research Team has over 300 Peer reviewed scientific publications to their credit.

Our Medical Director Keith March, M.D., Ph.D.

Dr. Keith March, M.D., Ph.D. Born June 4, 1963 Five Children Indiana University Ph. D. 1983 with Highest Distinction Indiana University School of Medicine M.D./Ph.D. with highest Distinction 1985 Post Doctoral: Indiana U. Medical Center Medical Article Author & Editorial

General Grand Council has donated over $1,534,000.00

World Class Researchers Our Center includes clinicians, biologists, physicists, chemists,engineers, and technology transfer support. The participants within the center are also interacting with a highly complementary ensemble of industrial partners forming an overall consortium, with boundaries extending beyond the center itself.

Our Participants Our key collaborators have been found at Indiana University, Methodist Research Institute, Indiana State University, Purdue University and Rose-Hulman Institute of Technology. These participants provide across-the-board applied research, technology and experimental design to support the basic science projects.

Research Medical Team Dr. Dongming Hou M.D., Ph.D. -People s Repub. of China; Post Doc Univ. of Heidelberg,Germany Asst. Scientist IU Investigating the mechanism of restenosis and examining techniques to prevent it.

Research Medical Team Dr. Dan Meldrum M. D. Michigan State Residency, Univ. of Colorado; Fellowship, Johns Hopkins University Asst. Prof. of Surgery at Indiana University.

Dr. Dan Meldrum s Research Investigating the mechanism of how the heart produces cell damaging cytokines (agents) during heart attacks or heart surgeries and targeting therapies to determine if blocking cytokines such as tumor necrosis factor (TNF) aids the heart. Dr. Meldrum has authored over 100 peer reviewed scientific publications.

Research Medical Team Dr. Jalees Rehman

Dr. Jalees Rehman M.D. Munich, Germany; Post Doc. At Univ. of Calif.; Residency at IU Internal Med.; Cardiology Fellow, IU Investigating the role of stem cells and progenitor cells in cardiovascular disease. Also studying growth factors secreted by fat tissue to investigate the relationship between obesity and heart disease.

Research Medical Team Dongni Feng, Research Technician Studying molecular mechanisms directing artery remodeling NanKai University, People s Republic of China

Research Medical Team Catharine Williams, Lab. Tech. Animal Science, Purdue University Cell isolation to differentiate cultured cells General Laboratory support and cell culture experiments.

Dr March consults with Emily Judy an IU student learning about vascular research.

What are our current projects? I am looking at ways for people to grow new blood vessels (angiogenesis) using special delivery methods for genes and even using one s own cells to convey the genes. I like to think that researchers today are working to develop the medicine for tomorrow. Dr. March 7-12-2002

CMMRF Director s Projects: 1. The Closer 2. Stimulating vessel growth around the heart. 3. Extensive research investigating the role of a variety of genes and cells and how they interact in vascular biology. 4. Implement clinical programs to provide excellent care to patients with all vascular diseases.

The Closer A Completed successful Cryptic Masons Director s Medical Project

ICVBM Project #1 The Closer

The Vascular Closer Patent in place and completed Produced by Abbott Vascular 500,000 sold in 2001 Increased production in the future Royalties returned to CMMRF Medical Center at Indiana University (IVCBM).

ICVBM Project #2 Recently ICVBM investigators have been experimenting with a groundbreaking technique to extract a special population of a patient s own cells from the fat tissue using liposuction. We have found that we can select cells that are like stem cells and may soon be able to re-introduce them into the patient s heart to enhance the growth of new blood vessels and possibly regenerate heart tissue.

ICVBM Project #3 Electronic Pulsation Device Non-Invasive device that uses electronic pulses to stimulate cell growth that produces a natural bypass around trouble areas in the coronary arteries.

Why is our research so important? Due to the length of time involved in developing a device like the Closer, it is necessary to think way ahead and advance research solutions to hasten clinical applications. To shorten this process, research dollars are critical. The more parallel efforts in place, the quicker solutions are found. Dr. March 7-12-2002

Maintaining open arteries after Angioplasty One novel approach being developed and tested in the ICVBM involves the use of devices emitting ultrasound energy inside arteries following stenting to help perform gene therapy and keep such vessels open.

Early diagnosis of Coronary Artery Disease Your ICVBM investigators are developing techniques that will detect early abnormalities in the blood vessels by imaging inflamed areas of blood vessels entirely non-invasively.

Our Cryptic Mason Goals 1. Continued monetary support of the ICVBM. 2. $10,000,000 Foundation corpus for continued funding of future research. 3. Your commitment/pledge today will ensure our future success.

Cryptic Masons Medical Research Foundation What We Have Done For Ourselves Alone Dies With US; What We Have Done For Others And The World Is Immortal Albert Pike

General Grand Council, Cryptic Masons, International